Business

Investor Center

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed’s drug candidates target disease cells and the blood vessels that nourish them. The company’s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation and inflammation—processes that are vital to the progression of cancer and other diseases.

Upcoming Events
There are no upcoming events at this time.

Webcasts and Presentations
Business Presentation - New York - Mar 27, 2008
March 25, 2008
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
View the webcast

Conference Call - Mar 13, 2008
March 6, 2008
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
A digital recording will be available approximately two hours after completion of the conference and will be accessible for 60 days. To access the recording, dial 800-642-1687 (U.S. or Canada) or 706-645-9291 (internationally) and enter the digital pin number 37155333.

Business Presentation - Feb 28, 2008
February 26, 2008
EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
Click here to view the archived presentation

Business Presentation - Feb 25, 2008
February 21, 2008
EntreMed to Present at the 7th Annual North America Forum for Investing and Partnering in Biotech
Click here to view the archived presentation

Webcast
February 5, 2008
EntreMed to Present at BIO CEO and Investor Conference
Click here to view the archived webcast

EntreMed In the News
Drug Discovery and Development
July 1, 2007
Drug Discovery and Development - EntreMed’s Roller Coaster Ride
Read the article

10-K Downloads
2004, 2005, 2006 2007

SEC Filings
View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. EntreMed, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the the information contained therein. Further, EntreMed takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.

Corporate Governance Documents
Code of Ethics, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter

Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem®; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).